MedTrace Logo

Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis

NCT04595045 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2022-08-09

No results posted yet for this study

Summary

Spastic paraparesis is one of the most disabling functional deficits in the population with multiple sclerosis between 18 and 80 years of age and at any functional level. Infiltration with Botulinum Toxin is a clinical practice that has been carried out for years with clinical evidence of improvement in the patient's walking patterns and quality of life. We assume that the infiltration of this product can generate a direct benefit in the walking ability of these patients and secondarily improve their quality of life.

Conditions

Interventions

DRUG

Botulinum toxin type A infiltrations

Echo-guided infiltration of botulinum toxin type A (Dysport®) in the lower limbs according to normal service practice

Sponsors & Collaborators

  • Aránzazu Vázquez Doce

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-24
Primary Completion
2022-07-28
Completion
2022-07-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04595045 on ClinicalTrials.gov